Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

226.93 +226.91 (+1004015.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 680,038
Open 0.0229
Bid (Size) 224.23 (100)
Ask (Size) 239.88 (100)
Prev. Close 0.0226
Today's Range 224.61 - 229.41
52wk Range 105.00 - 243.32
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?
Jazz Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 28.7%. The stock now trades at $232.44, mark... 
Via StockStory
Topics Stocks

Performance

YTD
+31.1%
+31.1%
1 Month
-1.1%
-1.1%
3 Month
+25.8%
+25.8%
6 Month
+37.6%
+37.6%
1 Year
+112.0%
+112.0%

More News

Read More
News headline image
Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ)
Via StockStory
Topics Artificial Intelligence Intellectual Property
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Presents a Decent Value Opportunity with Strong Valuation and Growth Potential ↗
Via Chartmill
Jazz Pharmaceuticals (NASDAQ:JAZZ) Flashes Perfect Minervini Trend Template Score with 116% Annual Surge ↗
Via Chartmill
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surges 3.7% After-Hours on Q1 2026 Revenue and EPS Beat ↗
Via Chartmill
News headline image
3 Unpopular Stocks We Find Risky
Via StockStory
Topics Credit Cards
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Healthcare Stocks We Think Twice About
Via StockStory
News headline image
3 Mid-Cap Stocks We’re Skeptical Of
Via StockStory
News headline image
Is Marriott Stock a Buy After GMT Capital Initiated a Position Worth Over $66 Million? ↗
Via The Motley Fool
News headline image
Jazz Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
Via StockStory
News headline image
JAZZ Q1 Deep Dive: Oncology and Neuroscience Drive Double-Digit Revenue Growth, Eyes on Upcoming Approvals
Via StockStory
News headline image
Jazz (JAZZ) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 Sales
Via StockStory
News headline image
Jazz Pharmaceuticals (JAZZ) Q1 Earnings Report Preview: What To Look For
Via StockStory
Topics Artificial Intelligence
News headline image
Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Overrated Stocks with Warning Signs
Via StockStory
News headline image
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead
Via StockStory
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
Via MarketMinute
News headline image
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
1 Value Stock to Research Further and 2 We Ignore
Via StockStory
News headline image
3 Healthcare Stocks Walking a Fine Line
Via StockStory
News headline image
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Jazz Pharmaceuticals plc - Ordinary Shares publicly traded?
Yes, Jazz Pharmaceuticals plc - Ordinary Shares is publicly traded.
What exchange does Jazz Pharmaceuticals plc - Ordinary Shares trade on?
Jazz Pharmaceuticals plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Jazz Pharmaceuticals plc - Ordinary Shares?
The ticker symbol for Jazz Pharmaceuticals plc - Ordinary Shares is JAZZ on the Nasdaq Stock Market
What is the current price of Jazz Pharmaceuticals plc - Ordinary Shares?
The current price of Jazz Pharmaceuticals plc - Ordinary Shares is 226.93
When was Jazz Pharmaceuticals plc - Ordinary Shares last traded?
The last trade of Jazz Pharmaceuticals plc - Ordinary Shares was at 06/17/26 04:00 PM ET
What is the market capitalization of Jazz Pharmaceuticals plc - Ordinary Shares?
The market capitalization of Jazz Pharmaceuticals plc - Ordinary Shares is 14.14B
How many shares of Jazz Pharmaceuticals plc - Ordinary Shares are outstanding?
Jazz Pharmaceuticals plc - Ordinary Shares has 14B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.